United States (National)
Not enough data
Natalie Bellini's coverage mainly focuses on diabetes, healthcare, and pharmaceuticals. Her articles predominantly feature industry-specific announcements and cite data to support the information provided.
Given her emphasis on diabetes management, Natalie would likely appreciate pitches from experts in the field offering insights into new technologies or treatments for diabetes. She may also be interested in receiving updates about medical conferences related to diabetes or healthcare education.
As she doesn't have a specific geographic focus mentioned, it is important to note that her primary interest lies in covering topics related to diabetes management and advancements within the healthcare sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Panelists discuss how teplizumab infusion requires specialized medical facilities equipped to manage intravenous therapy, monitor for potential adverse effects, and provide appropriate care during treatment to ensure patient safety and efficacy.
Panelists discuss how antibody screening tests for type 1 diabetes (T1D), including tests for insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD) antibodies, and other markers can help identify individuals at risk for developing the disease before clinical symptoms appear, enabling earlier monitoring and potential intervention.
Panelists discuss how screening for type 1 diabetes (T1D) should be considered for individuals at higher risk, such as those with a family history of T1D, autoimmune conditions, or certain genetic markers, to identify early signs of the disease and enable timely intervention.
Panelists discuss how the progression of type 1 diabetes (T1D) unfolds through distinct stages, from the preclinical phase of autoimmunity to the onset of clinical diabetes, emphasizing the importance of early detection and intervention to improve patient outcomes.
By: Javier Morales, Natalie Bellini
Panelists discuss how delaying intervention in stage 2 type 1 diabetes (T1D), when dysglycemia is present but clinical symptoms have not yet developed, can lead to further ß-cell deterioration and worsen long-term glycemic control, ultimately increasing the risk of complications.
By: Javier Morales, Natalie Bellini
Panelists discuss key insights on the importance of early screening for type 1 diabetes (T1D), the role of antibody testing in identifying at-risk individuals, and the need for timely intervention to preserve ß-cell function and optimize long-term management strategies for better patient outcomes.
By: Javier Morales, Natalie Bellini
Panelists discuss how teplizumab, an anti-CD3 monoclonal antibody, shows promise in delaying the onset and progression of type 1 diabetes (T1D) by modulating the immune response and preserving ß-cell function in high-risk individuals.
By: Diana Isaacs, Natalie Bellini
To celebrate surpassing 100 episodes, Diabetes Dialogue sits down with Irl Hirsch, MD, to discuss the 25-year anniversary of continuous glucose monitoring in 2024.
By: Diana Isaacs, Natalie Bellini
In this episode, hosts reflect on the advancement in CGM that reshaped care for diabetes and overall health during 2024.
By: Diana Isaacs, Natalie Bellini
In this episode, hosts discuss the efficacy of MariTide for obesity, a head-to-head comparison of semaglutide vs. tirzepatide, and concerns about GLP-1 agonist compounding.
(833) 317-6278 